Company Overview
Akums Drugs and Pharmaceuticals Limited, established in 2004, has become a leading entity in the pharmaceutical industry. As a contract development and manufacturing organization (CDMO), it serves markets both in India and internationally.
Key Services
The company provides a wide range of services, including:
- Comprehensive solutions for product development and manufacturing
- Research and development (R&D) of formulations
- Preparation and submission of regulatory dossiers for Indian and international markets
- Various testing services
- Manufacturing and sales of branded drugs and active pharmaceutical ingredients (APIs)
Manufacturing Capabilities
Akums boasts impressive manufacturing capabilities with:
- Ten manufacturing facilities with a combined annual production capacity of 49.21 billion units (as of September 30, 2023)
- Production of various dosage forms such as tablets, capsules, and liquid medicines
- Over 4,025 commercialized formulations across more than 60 dosage forms
Regulatory Accreditations
The company has received several significant regulatory accreditations, including:
- European Good Manufacturing Practice (EU-GMP)
- World Health Organization Good Manufacturing Practice (WHO-GMP)
- United States National Sanitation Foundation (US NSF)
Objectives of the IPO
The proceeds from the IPO are planned to be utilized for:
- Repaying or prepaying debt for the company and its subsidiaries
- Funding additional working capital requirements
- Supporting inorganic growth through acquisitions
- General corporate purposes
Summary of Financial Information:
Here's the updated code with the new data: ```html| Period Ended | 31-Mar-24 | 31-Mar-23 | 31-Mar-22 |
|---|---|---|---|
| Assets | 3,516.37 | 3,266.53 | 3,069.05 |
| Revenue | 4,212.21 | 3,700.93 | 3,694.52 |
| Profit After Tax | 0.79 | 97.82 | -250.87 |
| Net Worth | 709.5 | 717.19 | 621.98 |
| Reserves and Surplus | 861.01 | 868.7 | 787.79 |
| Total Borrowing | 491.56 | 536.97 | 357.95 |
Comparison with Listed Peers:
| Company Name | P/E | P/B | RoE (%) |
|---|---|---|---|
| Akums Drugs & Pharmaceuticals Ltd | 30 | 14 | 17 |
| Divi's Laboratories Ltd | 78 | 9 | 12 |
| Suven Pharmaceuticals Ltd | 80 | 12 | 16 |
| Gland Pharma Ltd | 43 | 4 | 10 |
| Torrent Pharmaceuticals Ltd | 61 | 15 | 25 |
| Alkem Laboratories Ltd | 35 | 6 | 11 |
| Eris Lifesciences Ltd | 37 | 6 | 18 |
| JB Chemicals & Pharmaceuticals Ltd | 53 | 10 | 19 |
| Mankind Pharma Ltd | 44 | 9 | 23 |
| Innova Captab Ltd | 38 | 4 | 28 |
Key details of the IPO:
IPO Dates: 30 July to 1 Aug, 2024
Price Band: Rs. 646 to Rs. 679 per share
Lot Size: 22 shares
Listing Date: 6 Aug, 2024
Total Issue Size: Rs. 1,856.74 Cr. (Fresh Issue = Rs. 680 Cr. )
Retail Quota: 10%
GMP: Rs. 180 (Only for information purposes.)
Note: For additional information & risk factors please refer to the Red Herring Prospectus
Join our WhatsApp Group for Trading/Investment ideas & Market Updates 👇
Disclaimer: We are not SEBI registered. All the views are personal and only for educational purposes. Do your due diligence before making any trading or investing decisions. The data provided in this blog post is for illustrative purposes only and does not constitute financial advice. Always consult with a qualified financial advisor before making investment decisions.
